Monoclonal antibody drugmaker United BioPharma Inc (聯合生技) yesterday said that its NT$1 billion (US$33.17 million) new plant in Hsinchu County would be able to produce 100kg of antibodies a year and satisfy the need for phase-three clinical trials and early market demand of a new drug.
The new plant will have two production lines, each with a 2,000-liter reactor, company executive director Shugene Lynn (林淑菁) said at an investors’ conference.
“We also reserved the space to build another 10 production lines for the new factory. With the extra lines, United Biopharma will be able to make 600kg of antibodies per year in the future and satisfy the demand of a new drug for the global market,” she added.
Construction is to begin by the end of this year and the factory is expected to be operational in 2016, Lynn said.
The company is developing three monoclonal antibody drug treatments and four monoclonal antibodies for use as biosimilars, company president Liao Mei-june (廖美君) said.
Among these antibodies, UB-421, which is used to treat AIDS, has completed phase-two clinical trials, while the company is to file an investigational new drug application for UB-621, which targets the Herpes simplex virus, by early next year, Liao said.
Other drugs made by the company are still in preclinical trials, she added.
United BioPharma plans to debut on the local Emerging Stock Market (興櫃市場) on Friday, with shares set at NT$85, the company said.
The debut is earlier than the time the company set in November last year.
The company will not release additional shares in its debut, said Victor Sun (孫潤本), the company’s special assistant to the chairperson.
The company’s capital is set at NT$1.15 billion, it said.
United Biomedical Inc Asia (聯亞生技), which manufactures and sells multiple medical products, owns 65 percent of United BioPharma’s shares, while Formosa Plastics Group (台塑集團), the nation’s largest industrial group, owns 25 percent, it added.
In the first half of this year, United Biopharma posted losses of NT$68.41 million, or NT$0.58 per share, because of R&D expenditures of NT$61.48 million, according to the company’s filing with the Taiwan Stock Exchange.
The company does not have comparable data for a year ago, as it was founded on Jan. 16.
Company chairperson Wang Chang-yi (王長怡) said United Biopharma plans to spend less than NT$200 million this year on R&D.
Although it has not yet reported revenue, the company expects to book licensing income next year, Wang said, without offering further information.
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Huawei Technologies Co’s (華為) latest smartphones carry a version of the advanced made-in-China processor it revealed last year, results from an independent analysis showed. This underscored the Chinese company’s ability to sustain production of the controversial chip. The Pura 70 series unveiled last week sports the Kirin 9010 processor, research firm TechInsights found during a teardown of the device. This is a newer version of the Kirin 9000s, made by Semiconductor Manufacturing International Corp (SMIC, 中芯) for the Mate 60 Pro, which had alarmed officials in Washington who thought a 7-nanometer chip was beyond China’s capabilities. Huawei has enjoyed a resurgence since
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li